(All times shown as Eastern Standard Time, EST)
| 08:00 – 08:15 | Welcome & Logistics | Stephane Bancel and Melissa Moore |
| 08:15 – 09:45 | Session I: mRNA Biology and Translation | Chair: Melissa Moore |
| 08:15 – 08:40 | Single-cell transcriptome imaging and cell atlas of complex tissues | Xiaowei Zhuang (HHMI/Harvard Chemistry) |
| 08:40 – 09:05 | Colliding ribosomes function as a gauge for activation of cellular stress responses | Rachel Green (HHMI/Johns Hopkins Medical School) |
| 09:05 – 09:30 | Development of RNA structures for cancer immunotherapy |
Kyuri Lee (Gyeongsang National University) |
| 09:30 – 09:45 | Decoding mRNA translatability and stability from the 5’UTR | Shu-Bing Qian (Cornell University) |
| 09:45 – 10:00 | Break | |
| 10:00 – 10:05 | Keynote Introduction | Stephane Bancel |
| 10:05 – 10:30 | Keynote Speaker Please note: Taped talk – No Q&A |
Anthony Fauci (NIAID/NIH) |
| 10:30 – 11:00 | Break | |
| 11:00 – 12:55 | Session II: Delivery | Chair: Dan Siegwart |
| 11:00 – 11:20 | mRNA Delivery | Dan Anderson (MIT) |
| 11:20 – 11:40 | Biomaterials strategies to enhance and prolong the effects of therapeutic mRNA | William L. Murphy (U.Wisconsin-Madison) |
| 11:40 – 12:00 | Supramolecular assemblies for enhanced mRNA delivery | Horacio Cabral (U. Tokyo) |
| 12:00 – 12:20 | Boosting intracellular delivery of messenger RNA | Gaurav Sahay (OHSU) |
| 12:20 – 12:40 | Advancing pulmonary delivery of mRNA therapeutics for the treatment of genetic diseases | John Androsavich (Translate Bio) |
| 12:40 – 12:55 | COATSOME SS-Lipids as novel, biodegradable, ionizable Lipids for mRNA Therapeutics and Vaccines | Syed Reza (NOF America) |
| 12:55 – 13:10 | Break | |
| 13:10 – 14:40 | Session III: Prophylactic and Therapeutic Vaccines | Chair: Norbert Pardi |
| 13:10 – 13:30 | Development of broadly protective influenza virus vaccines using nucleoside-modified mRNA | Norbert Pardi (UPenn) |
| 13:30 – 13:50 | A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-1 specific immunity | Justin M Richner (University of Illinois) |
| 13:50 – 14:10 | Intranasal mRNA Vaccines: COVID and far beyond | Wim Tiest (Etherna) |
| 14:10 – 14:25 | Therapeutic vaccination of cancer patients with WT1 mRNA-electroporated dendritic cells: Using mRNA as an active substance in the clinic since 2005 | Zwi Berneman (Antwerp Univ Hospital) |
| 14:25 – 14:40 | Immunodominant Malaria Antigen, pfcsp Induces Functional, Protective Immune Responses in Mice using mRNA Platform | Katherine Mallory (Walter Reed Army Institute of Research) |
| 14:40 – 14:55 | Developing an mRNA Vaccine Platform Across Multiple Infectious Disease Targets | Danilo Casimiro (Sanofi) Frank DeRosa (TranslateBio) |
| 14:55 – 15:10 | Break | |
| 15:10 – 16:30 | Session IV: Manufacturing, Analytics and Commercialization | Chair: Patrick Baumhof |
| 15:10 – 15:30 | Meeting the quality and scale requirements for IVT enzymes in the production of therapeutic mRNAs | John Pelletier (New England Biolabs) |
| 15:30 – 15:50 | Strategic CDMO partnering for accelerated mRNA vaccine development: A COVID-19 case study | Anton McCaffrey (TriLink BioTechnologies) |
| 15:50 – 16:10 | Characterizing the therapeutic application of mRNA-lipid nanoparticles | Thomas Madden (Acuitas) |
| 16:10 – 16:30 | Enabling mRNA Platform Commercialization and Setting Up for Future Success | Tadas Trunca (Thermo Fisher) |
Click here for our privacy policy.
